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IntroductIon
Hepatitis C virus (HCV) is a leading cause of liver-related mor-
bidity and mortality worldwide, especially in Mediterranean 
countries where prevalence rates range from 1 to 3% in the 
general population [1]. In Spain, the latest population-based data 
collected during 2016 estimated anti-HCV and viremic (HCV-
RNA detectable) prevalences lower than expected (1.2 and 0.4%, 
respectively) [2, 3].
The problem is exacerbated in prisons and other closed settings 
(i.e. jails, pre-trial detention centers, psychiatric institutions, etc.), 
where a high prevalence of risk behaviors, mainly injection drug 
use (IDU), is associated with a nearly ten times higher prevalence 
of HCV infection than that of the general population [4]. Accord-
ingly, a recent observational study carried out in 2011 on 18 Span-
ish prisons revealed a prevalence of HCV infection of 22.7% [5]. 
Seroprevalence in Western European and US prisons is slightly 
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lower (15.5% and 15.3%, respectively) [6]. Some intrinsic circum-
stances aggravate the problem, such as a substantial risk of HCV 
transmission during incarceration and after release, favored in part 
by an unawareness rate up to 25% [7].
Testing HCV in high-risk populations and subsequently treat-
ing the infected populations has been recommended for years as 
an epidemiological prevention measure to control a widespread 
infection, and also to prevent disease injury on an individual basis 
[8]. However, there have been several classical barriers that have 
limited the universality of these policies [4, 9]: lack of treatments 
with high beneficial/risk ratios and costs of treatments that influ-
ence on healthcare budgets of closed settings; penitentiary health 
care managed within each country by public agencies with dif-
ferent sensitivity to the health problem posed by prisons; persis-
tence of indoor risk practices favouring intraprison transmission; 
limited capacity to access hospital-based hepatitis specialists; lack 
of specialist nurses; complex health care needs of prisoners; high 
detainee turnover, etc. The advent of powerful and safe direct-
acting antivirals (DAAs) in the last years, and the implementation 
of more rational penitentiary policies in terms of prevention and 
healthcare access must aid to face these challenges [10].
It has been recently advocated that a strategy based on “micro-
elimination” programs targeted on risk populations like prisoners 
may allow authorities to achieve the World Health Organization 
(WHO) commitment of eliminating viral hepatitis B and C as pub-
lic health threats by 2030 [11]. Up to now, there have been some 
experiences of epidemiological surveillance and even treatment 
programs in selected prisons [7, 12]. Nevertheless, they all lack 
generalization or even maintenance of these programs, probably 
due to the aforementioned barriers.
The objective of this study was to design and evaluate a pro-
ject for the elimination of HCV in a penitentiary center through 
the development of a sustained health care model based on three 
premises: (1) the creation of true multidisciplinary teams to care 
for infected inmates, (2) a universal screening and treatment strat-
egy with DAAs, and (3) the use of telemedicine as a support tool.
MEtHods
Study design and population
This was an open-label, single-arm, phase-IV clinical trial 
of low-grade of intervention (Clinicaltrials.gov Identifier: 
NCT02768961). It was carried out between May 2016 and July 
2017 in the penitentiary center of “El Dueso” in Santoña (Canta-
bria, Spain).
The program was directed to the whole inmate population 
imprisoned during this period (i.e. both the baseline population 
at the beginning of the study and all new admissions). Age higher 
than 18 and acceptance to participate were the only eligibility 
criteria.
Phases of the project and professional network
The project was carried out on the basis of a multidisciplinary 
collaboration between the prison and the Valdecilla University 
Hospital. It was structured into five phases (Fig. 1). The first phase 
consisted of creating a multidisciplinary professional network and 
defining the specific relationships between the different agents 
involved (Fig. 2). The team was coordinated by hepatologists and 
was supported by an expert on telemedicine. The second phase 
consisted of recruiting the inmates and performing a universal 
screening of viral diseases. Every patient was asked to participate 
in the study, and if they agreed, they signed the informed consent. 
At baseline, variables including anthropometrics, demograph-
ics, risk behaviors, medical history, particularly if related to HCV 
infection and psychiatric conditions, were recorded. A serum 
sample that included a complete blood cell count, biochemistry 
and viral markers (HBsAg, anti-HBs, anti-HBc, anti-HCV and 
anti-HIV) was also obtained. Quantification of hepatitis B virus 
DNA was determined in HBsAg positive individuals by polymer-
ase chain reaction.
HCV infection characterization (i.e. viremia and genotype, 
clinical and pharmacological history, ultrasonography and Fibro-
Scan® -Echosens™ NorthAmerica; 1050 Winter Street, Waltham, 
MA 02451, USA-), and the subsequent systematic treatment of 
viremic patients were performed in the third and fourth phases of 
the study, respectively. Finally, a fifth phase of follow-up was imple-
mented in order to maintain the program over time and to detect 
new incident cases of HCV (i.e. intraprison transmission). Thus, 
all new admissions were proposed to participate in the program, 
and the whole population study, infected or not at baseline, were 
re-evaluated every 6 months and upon release, and any relapse or 
new infection was offered to be treated. In addition, a strategy of 
follow-up was planned for those treated patients who left prison, 
either because they were transferred to another prison, or because 
they reached freedom. In the former group, health care providers 
at El Dueso contacted their colleagues at other centers to gather 
information, whereas in those released follow-up was performed 
in our hospital.
Interventions
Every chronic infected patient whose stay in prison was expected 
to be longer than 30 days was offered treatment in accordance with 
the Spanish National Strategy Plan for the Hepatitis C (SNSPHC) 
in force at the beginning of the study [13]. In order to assure 
adherence two main decisions were adopted: (1) to treat every 
patient with the simplest antiviral regimen based on a fixed-dose 
combination tablet containing 400 mg of sofosbuvir and 90 mg of 
ledipasvir (Gilead Sciences, Inc., Foster City, CA 94404), admin-
istered orally once daily without ribavirin. This combination was 
selected according to the aforementioned Spanish guidelines and 
taking into account the specific availability of antiviral drugs dur-
ing the study period in our region. This policy was established by 
the regional Department of Health, and for example, precluded the 
prescription of other schemes (i.e. sofosbuvir+daclatasvir for gen-
otype 3). Therefore, the industry financial support in the study did 
not influence in any way the decision to treat patients with this sin-
gle DAA combination. Treatments were prescribed by one hepa-
tologist and lasted 8–12 weeks according to the characteristics of 
the disease; (2) to administer the therapy under direct observation 
supervised by the staff from El Dueso health department. During 
the periods in which detainees were out of prison, a counting pill 
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Follow-up
A teleconsultation program between the prison and the hospital 
was established to follow-up patients and monitor therapy. It was 
established by the video collaboration tool “Reúnete-Red SARA”, 
available to all public administrations in Spain [14]. Thus, face-to-
face consultations at the hospital were replaced by teleconsulta-
Phase 1:




Recruitment / informed consent
Universal screening to all inmates.
Phase 3:
Complete characterization of viremic patients
Phase 4:
Treatment of all patients
Phase 5: Follow-up.
- Surveillance of new infections
whether previously infected or not.
- Recruitment and screening the new
inmates.
- Treatment of new infections and
rescue therapies for non-responders.



















Fig. 2 Schematic representation of the multidisciplinary professional network created to care the inmate population. “Reúnete-Red SARA” refers to the 
video collaboration tool, available to all public administrations in Spain (https://administracionelectronica.gob.es/ctt/redsara#.WOjGtJQhXqA), which served 
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tions (baseline, week 4, end of treatment “EOT” and 12, 24 and 48 
weeks after EOT). This tool not only served as a simple telecon-
sultation between patient and physician as previously described 
in this setting, but was also used to develop a complete inter-
professional network of assistance [15]. Quality and satisfaction 
of teleconsultations were evaluated through a self-administered 
questionnaire divided into 11 questions, each of them being 
assessed by a 5-point Likert scale (Table  1). Finally, all adverse 
events (AEs) were recorded and serious AEs were monitored 
throughout the study. All AEs were coded using the Medical Dic-
tionary for Regulatory Activities.
Outcomes
Primary endpoint. The primary objectives were to determine the 
prevalence of HCV viremia at July 23, 2017, and the incidence of 
new cases of HCV infection (i.e. intraprison transmission) during 
the study period.
Efficacy assessments. Plasma HCV-RNA levels were measured 
with the use of the COBAS TaqMan HCV-RNA assay, version 2.0 
(Roche Molecular Systems, Pleasanton, CA), with a lower limit of 
quantification of 25 IU per milliliter and a lower limit of detection 
of 10 IU per milliliter. HCV-RNA levels were measured at base-
line, at weeks 4, 8, 12, and at the follow-up visit held 12 weeks after 
EOT. A sustained virologic response (SVR) was defined as a viral 
load <10 IU per milliliter 3 months after EOT.
Phylogenetic analysis. Phylogenetic analysis of the nucleotide 
sequences obtained was carried out in order to investigate any 
possible epidemiological linkages among patients that could 
help to distinguish between persistent infection, reinfection, and 
super-infection. Consequently, blood samples were obtained for 
viral sequencing at baseline and at any time during or after EOT 
in those patients who either did not meet the criteria for a SVR, 
experienced a breakthrough, a relapse, or those who became 
viremic after achieving a documented SVR. Part of hypervari-
able region 1 (HVR1) of the hepatitis C genome was amplified 
and sequenced in samples from all HCV RNA-positive patients. 
The HVR1 fragment (nucleotide positions 1156–1234) was cho-
sen for sequence analysis because this domain exhibits a suffi-
ciently high degree of variability to allow analyses to distinguish 
between HCV isolates of the same subtype. The HVR1 fragments 
isolated from the patients were aligned by using the SeaView pro-
gram [16, 17].
Sample size. The study was intended to test the whole inmate 
population and to treat all chronic infected patients who accepted 
to participate. Therefore, no sample size was calculated.
Patient involvement. Prisoners were involved in some parts of the 
design of the study. Thus, some informative meetings were carried 
out between the investigators, prison health care providers and 
the inmate population before defining the protocol. These meet-
ings served to explain the importance of different epidemiologi-
cal preventive measures against infectious diseases and the current 
opportunities of treatment against HCV chronic infection. Two 
major decisions were taken after explaining the design and dis-
cussing it: to definitely accept telemedicine as a consultation tool 
and to use the shortest regimens avoiding the use of ribavirin.
Ethics. The study was approved by all Institutional Review Boards 
(IRB) and by the Ethics Committee of Cantabria (act 20/2015) 
and was conducted in compliance with the Declaration of Hel-
sinki and International Conference on Harmonization guidelines. 
A designated member of the IRB was in charge of monitoring the 
trial in order to ensure independence, autonomy, and justice in 
this environment. Periodical visits to the investigators and even to 
the penitentiary center were consequently scheduled. Throughout 
the study prisoners were free to question the investigators and to 
refuse to participate without any repercussions during the incar-
ceration period. All patients included signed a written informed 
consent provided before enrollment.
Statistical analysis. A descriptive analysis was performed. Cat-
egorical variables were described with percentages, and continu-
ous variables were described with mean and standard deviation 
or median and range/interquartile range (IQR) as appropriate. A 
95% confidence interval (CI), was used to estimate proportions. 
The statistical analysis was performed with SPSS Statistics for 
Windows, Version 21.0 (IBM Corp, Chicago, Armonk, NY, USA). 
All p-values were two-tailed. Statistical significance was defined 
as p < 0.05.
Table 1 Telemedicine satisfaction assessment through a self-
administered questionnaire based on a 5-point Likert scale
Question Score
Mean SD
Q1 I was able to see the doctor through the screen 4.5 0.6
Q2 I was able to hear the doctor well through the 
speakers
4.2 1.1
Q3 the doctor could hear me without trouble 4.4 0.8
Q4 I felt comfortable talking to the doctor through the 
screen
4.6 0.9
Q5 When I started the consultation I was not more 
nervous than usual
4.0 1.4
Q6 During the consultation I was relaxed 4.5 1.2
Q7 I could explain what I wanted to the doctor 4.5 1.2
Q8 I understood the instructions the doctor gave me 4.7 0.5
Q9 I am in accordance with the timeliness of  
consultation
4.2 1.3
Q10 My privacy and confidentiality was respected 4.6 1.4
Q11 Overall, I am satisfied with the service received 4.7 0.6
Each question was scored through a 5-point Likert scale:
1: strongly disagree, 2: disagree, 3: neither agree nor disagree, 4: agree, 5: 
strongly agree. Questions that scored >4 points indicate high level of satisfaction.
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rEsults
Characteristics of the study population
An offer to participate was given to 851 inmates (420 of them rep-
resented new admissions during the study period) (Fig. 3). Base-
line and new-admitted inmates had similar demographic, clinical, 
and virological characteristics. Only four inmates (0.5%) refused 
to participate. All the participants were Caucasian with a median 
age of 36 years (range 18–78 years) and most of them were male 
(95.9%). Sixty-five inmates (7.6%) were active IDU and followed 
a needle exchange program in prison, whereas 57 (6.7%) were 
on opioid substitution therapy. Table 2 shows the demographic, 
clinical, and virological characteristics of both the whole inmate 
population and those chronically infected. HCV antibodies were 
present in 110 inmates (13.0; 95 CI, 10.9–15.4%), being this pro-
portion higher in the IDU population (47.7; 41.2–54.3%). Over-
all, 86 (10.2; 8.3–12.4%) had detectable HCV-RNA (11 of them 
being co-infected with HIV). Therefore, 78.2% of seropositive 
inmates were viremic. Most chronic HCV patients had genotypes 
1 or 3 (82.6%) and presented a low fibrosis stage (F0–F1, 52.2%), 
although 25% were cirrhotic (Table 2).
Efficacy and safety
Seventeen out of 86 viremic patients whose confinement period at 
the center was expected to be lower than 30 days were excluded 
from the treatment phase. They were informed of their disease 
and of the feasibility of treatment once outside. The remaining 69 
viremic patients accepted and started the treatment. The major-
ity of patients (n = 65, 94.2%) were treated for 12 weeks (Table 2). 
All HIV co-infected patients were on highly active antiretroviral 
therapy and no changes in their regimen were made while on DAA 
treatment. At the time of this writing, 66 out of 69 patients have 
completed the scheduled treatment. Two of them were lost to fol-
low-up upon their release from prison (both of them had already 
finished the treatment and they had showed EOT response). The 
remaining three patients are currently on treatment and all of them 
have undetectable viremia so far. Of the 64 patients with an evalua-
tion of the response, only three were non-responders (Fig. 4). SVR 
was 92.4% (83.5–96.7%) by intention to treat analysis and 95.3% 
(87.1–98.4%) by per-protocol (PP) analysis. All failures consisted of 
viral breakthrough during treatment in naïve, genotype 3 patients 
with different stages of fibrosis (F2 or F4). Two of them were HIV 
co-infected. All three cases had been treated for 12 weeks and had 
exhibited a correct adherence to the treatment (≥90%). Phyloge-
netic analysis showed that all the cases analyzed were recurrences 
and not reinfections. They were successfully rescued with a 12-week 
length salvage regimen (sofosbuvir, elbasvir/grazoprevir, and riba-
virin) yielding an average SVR of 96.9% (89.6–99.2%) by ITT. 
The mean treatment adherence throughout the study was 99.3% 
(SD = 2.3%). Seven patients obtained a 3-day legal permission to 
leave prison while they were on treatment. All of them received 
the medication for that period, declared to have taken it correctly, 





Anti-vhc (n = 110)
Seroprevalence 13.0%
Screening rejection (n = 4)
Screening rate 99.5%
Admissions (n = 420)
Excluded (n = 17*)
On treatment  (n = 3)Completed treatment (n = 66)
ITT analysis
Response evaluation (n = 64)
PP analysis
Lost to follow up (n = 2)
HCV-RNA+ (n = 86)
Viremia prevalence: 10.2%
Treated (n = 69)
Fig. 3 Flow-chart of the study. *Patients whose confinement period at the center was expected to be lower than 30 days were excluded of the fourth  
(treatment) phase of the study. they were informed of their disease and possibilities of treatment in other centers or after leaving the prison. †Refers to 
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Two patients had to be hospitalized because of hepatic decom-
pensation (variceal hemorrhage and ascites, respectively), but 
they could return to prison and resume the treatment after being 
appropriately treated. Both were genotype 1 cirrhotic patients 
with the following baseline characteristics: MELD score (12/12); 
platelet count (67/70 × 109/L) and albumin serum levels 
Table 2 Baseline characteristics of (A) the whole inmate 
population included from May 2016 to July 2017 and (B) inmates 






Age, median (range), year 36 (18–78) 44 (19–61)
Male, no. (%) 813 (95.9) 67 (97.1)
BMI, mean (SD), kg/m2 25.3 (3.9) 25.3 (5.0)
time of reclusion, median (range), 
weeks
270 (4–1.026) 245 (6–1.026)
Current or previous IDu, no. (%) 220 (25.9) 64 (92.7)
IDu on a syringe exchange program, 
no. (%)
65 (7.6) 13 (18.8)
Opioid substitution therapy, no. (%) 57 (6.7) 23 (33.3)
Active smoke habit, no. (%) 703 (82.9) 64 (92.8)
History of alcohol abuse, no. (%) 123 (14.5) 36 (52.2)
Comorbidities, no. (%)
  Psychiatric disorders 155 (18.3) 30 (43.5)
  Diabetes mellitus 33 (3.9) 6 (8.7)
  Dyslipemia 59 (6.9) 8 (11.6)
  Hypertension 69 (8.1) 6 (8.7)
 Anti-HIv+ve, no. (%) 21 (2.5) 11 (15.9)
 HBsAg+ve, no. (%) 4 (0.5) 0 (0)
 Anti-HBc+ve, no. (%) 90 (10.6) 22 (31.9)
 Anti-HCv+ve, no. (%)
  General population 110 (13.0) 69 (100)
   Subjects with previous or current 
IDu
105 (47.8) 64 (100)
 Detectable HCv RNA, no. (%)c 86 (10.2) 69 (100)
Coinfection rate, no. (%)
  HIvd 11 (1.3) 11 (15.9)
  HBv 0 (0) 0 (0)
  HIv-HBve 1 (0.1) 0 (0)
 Baseline HCv RNA [log10 Iu/mL, 
median (IQR)]
5.9 (5.5–6.4)
HCv genotype, no. (%)
  1/1a 20 (29.0)
  1b 9 (13.0)
  3 28 (40.6)
  4 12 (17.4)
Fibrosis stage distribution (Fibroscan)
  F0–1 36 (52.2)
  F2 9 (13.1)
  F3 7 (10.1)
  F4 17 (24.6)














Fig. 4 Sustained viral response (SvR) according to HCv genotype.  






Analytical parameters (median [range])
  Alanine aminotransferase (u/L) 39 (9–401) 67 (10–401)
  total bilirubin (mg/dL) 0.5 (0.2–2) 0.6 (0.2–2)
  Albumin (g/dL) 4.5 (3.2–4.9) 4.3 (3.2–4.9)
  Creatinine (mg/dL) 0.9 (0.3–2.2) 0.8 (0.3–1,17)
  INR 0.9 (0.8–2.2) 1.1 (0.9–1.5)
  Platelet count, ×109/L 185 (36–380) 177 (36–344)
 MELD, median (range) 9 (6–13)
DAA regimen
   Ledipasvir/sofosbuvir 8 weeks, no. 
(%)
4 (5.8)
   Ledipasvir/sofosbuvir 12 weeks, 
no. (%)
65 (94.2)
HCV hepatitis C virus, BMI body mass index, IDU injection drug use, anti-HIV 
antibodies against human immunodeficiency virus, HBsAg hepatitis B surface 
antigen, anti-HBc antibodies against hepatitis B core antigen, anti-HCV  
antibodies against hepatitis C virus, RNA ribonucleic acid, HIV human  
immunodeficiency virus, HBV hepatitis B virus, INR international normalized 
ratio, MELD model for end-stage liver disease, DAA direct-acting antiviral agents
aRefers to the sum of all inmates detained at the beginning of the study or 
baseline inmate population (n = 431) and all new admissions until July 2017 
(n = 420)
bRefers to those chronic HCv infected who initiated treatment (17 patients were 
excluded; see text)
cPlasma HCv RNA levels were measured with the use of the COBAS taqMan 
HCv RNA assay, version 2.0 (Roche), with a lower limit of quantification of 25 Iu 
per milliliter and a lower limit of detection of 10 Iu per milliliter
dRefers only to patients with active HCv infection
eRefers to an HIv co-infected patient on HAARt, with a previously cured HCv 
infection (responsive to a pegylated interferon and ribavirin regimen), and with a 
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3.7/3.4 g/dL respectively. In both cases a SVR was obtained. No 
other serious adverse events were notified and no patient had to 
withdraw the treatment due to intolerance.
Primary outcomes
At the end of the observational period there were 409 inmates 
in El Dueso. At this point, no inmate had detectable HCV-RNA, 
which represents a prevalence of 0% (0.0–0.9%).
Similarly, there were no new cases of HCV infection during 
follow-up. Thus, a negligible incidence equivalent to 0 per 100 
person-years could be estimated in this period. As a comparison, 
in 2015 the incidence of new cases of HCV infection had been 1.7 
per 100 person-years.
By the time of this writing, 16 out of 64 treated patients whose 
response was evaluated during the study have left prison (nine of 
them reached freedom and seven were transferred to other peni-
tentiary centers) (Fig.  5). Among them, 15 (93.8%) have had a 
scheduled follow-up without evidence of reinfection whereas one 
patient has lost follow-up (he was transferred to another prison, 
got freedom and lives in other Spanish region). At the moment, 
the median time that elapsed from the evaluation of the response 
to the last viremia determination is 12 months (5.5–14).
To sum up, as a whole there were only three relapses that were 
successfully rescued with a salvage regimen; neither, new (de 
novo) infections nor reinfections were recorded throughout the 
study period.
Evaluation of telemedicine satisfaction
All treated patients (n = 66; 100%) experienced teleconsulta-
tions and answered the satisfaction questionnaire (Table 1). The 
mode score was 5 (range: 1–5) with a mean score of 4.5 points 
(SD = 0.2).
dIscussIon
This study was intended to eliminate chronic HCV infection in a 
Spanish prison through implementing a systematic “test and treat” 
strategy with DAAs. Under this approach, 14 months after the 
beginning of the program the HCV-viremia prevalence dropped 
from 10 to 0% and the incidence of new cases of HCV infection 
also dropped from 1.7 per 100 person-years to 0 per 100 person-
years. These successful outcomes seem to be related to a high effi-
cacy of the treatment (96.9% of SVR by ITT) and high adherence 
to the program (>99%). The implementation of telemedicine as a 
support tool showed a great acceptance rate among inmates. As 
far as we know, this is the first sustained program of systematic 
“test and treat” with DAA against HCV that has virtually elimi-
nated the hepatitis C viremia in a prison.
Although the management of penitenciary healthcare has 
improved considerably throughout recent years, it still faces bar-
riers that limit the goal of achieving an equitable and non-dis-
criminative health care access for inmates. As a reflection of this 
situation, in the El Dueso prison in the previous 5 years only 53 
antiviral treatments were administered and all of them were based 
on the administration of Peg-interferon and ribavirin. The imple-
mentation in prisons of a program of eradication of HCV based 
on interferon-free DAA-based regimens searches the former goal 
and also adds to the benefit of treating addictions and the intrinsic 
role of social rehabilitation of prisons. Thus, imprisonment 






















every six months at HUMV
(n= 9)
Reinfection 0%
Fig. 5 Flow-chart of treated HCv prisoners whose response was evaluated and left the prison*. *Either after being transferred to another prison or after 
getting freedom; 1three genotype 3 patients had a virological breakthrough after the scheduled (sofosbuvir and ledipasvir) regimen but were successfully 
rescued with a 12-week length salvage regimen (sofosbuvir, elbasvir/grazoprevir and ribavirin); 2One participant who got freedom (no follow-up data avail-
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individuals [9, 18]. In addition to the beneficial effects at an indi-
vidual level, HCV elimination in prisons would generate relevant 
benefits for public healthcare [4]. Indeed, it is well known the 
persistence of high-risk behaviors both indoor and after release 
from incarceration (especially among people with substance use 
disorders), favouring HCV infection and transmission inside and 
ouside prison [19]. Although our program only proved its suc-
cess in preventing new incident cases of HCV infection during 
incarceration, it can be expected a lower infective capacity from 
the ex-convicts towards the community after release. A reha-
bilitation program that includes specific measures addressed to 
drug addictions (i.e. talks, individual consultations, voluntary 
group sessions, psychological support, drug detoxification and a 
Needle-Exchange Program), and sexual risk behaviors, has been 
incorporated in El Dueso and could help to prevent reinfections. 
In fact, it could be speculated that spreading this strategy to 
other prisons could entail individual and public health benefits 
in the near future, but also opportunities for equity and 
health [4, 9, 18, 20].
Certainly, budgetary considerations need to be taken into 
account in order to direct monetary resources towards the most 
cost-effective health actions. An agent-based simulation cost-
effectiveness model [treatment as prevention of HCV (TapHCV)] 
[21] has recently been adapted to the Spanish prisons [22]. This 
simulation considered HCV transmission, HCV prevalence, natu-
ral history of HCV progression, screening for HCV, and treatment 
with oral DAAs (at an average cost per treatment of €8055). The 
study concluded that prioritizing inmates by their health state is 
the most cost-effective strategy, resulting in an ICER of €9162 per 
QALY (using the commonly accepted willingness-to-pay thresh-
old of €24,000 in Spain). However, a sensitivity analysis showed 
that even treating all HCV-infected inmates would further reduce 
the HCV burden and is cost-effective, with the ICER of €21,750 
per QALY. Similarly, two recent mathematical models performed 
in the UK and the USA have demonstrated that universal opt-out 
HCV screening is cost-effective, particularly, if short-course IFN-
free DAAs were used and IDU treatment rates were increased [21, 
23]. Previous experiences have demonstrated that HCV treatment 
in incarcerated populations is feasible and meets the standard 
criteria for cost-effectiveness [12, 24]. A recent report describes 
the experience in three major Italian prisons of a program of test 
and treat chronic HCV inmates with DAAs only for those with 
advanced disease (F3–F4) according to Italian guidelines [7]. The 
“El Dueso” experience goes further in terms of extending treat-
ments to all fibrosis stages, universal use of DAAs, and sustain-
ability of the program over time, intending to become a real 
HCV-reservoir elimination program. Australian institutions are 
also developing interventional programs of screening and treat-
ment in prisons [9].
Telemedicine technologies are being integrated into health 
systems, which can help improve access to specialty care in 
isolated populations. Proof of this was the ECHO project in 
New Mexico, an educational intervention designed to transfer 
subspecialty knowledge about HCV to primary care providers, 
thereby increasing patient access to HCV care [25]. Telecare has 
also showed effectiveness in the management of HCV-infected 
patients [26]. The use of telemedicine in this project has 
sought to eliminate barriers in the management of a vulner-
able population (i.e. improving communication between health 
professionals, facilitating the inmate’s access to the specialist, 
preserving their privacy and avoiding painful stigmatizing 
transfers). The selection of this form of consultation by inmates 
in the early phases of the study design and, subsequently, its high 
degree of satisfaction support its usefulness in settings such as 
prisons.
Clinical research in prisoners or other people whose liberty is 
restricted has been controversial from an ethical point of view. 
However, experts encourage it with the overall goal of permitting 
scientifically rigorous research to the extent it confers significant 
benefit without undue risk and in accordance with the prisoner’s 
wishes and the recognition of their autonomy [27]. This low-grade 
interventional study fulfilled these premises, assured both a good 
level of prisoner involvement even in the design of the study, and a 
strict IRB monitorization of the study conduction. In other words, 
the individual rights prevailed over the general interest of the 
investigation.
Our study has some limitations. First, the exportability of the 
Jailfree-C experience to other areas and countries might be ham-
pered if its conditions are not met (i.e. low-medium inmate popula-
tion, telemedicine support, commitment of public institutions). In 
this sense, the recent SNSPHC approved in 2015 consider prisons 
as high priority centers of actuation [13] and cover its treatment 
for the next 3 years. Moreover, a program like the one described 
here may be more complex in other closed settings with a higher 
“turnover” of patients (i.e. jails, pre-trial detention centers, addic-
tion centers, etc.). Likely, each of this kind of environment needs 
a specific micro-elimination policy directed to its special idiosyn-
crasy. Second, the full implementation of the program might be 
limited by patients that escape from the program when they are 
transferred to other centers. This limitation most certainly did 
not happen in the El Dueso prison, since these cases were few and 
consisted of patients whose stay in the center was expected to be 
less than 30 days. Finally, it could be speculated that some patients 
could have received a suboptimal regimen, particularly those with 
HCV genotype 3. However, the regimen was selected according 
to the Spanish guidelines in force at the beginning of the study, 
and the overall efficacy of the regimen was very high in genotype 
3 patients (89.3% per ITT) as recently reported [28]. Moreover, all 
virological failures were adequately rescued with salvage thera-
pies. At the time of this writing, the program is on going and all 
inmates continue to receive a personalized IFN-free treatment 
according to the current European guidelines and most of pris-
oners are currently treated with pan-genotypic regimens (mainly 
sofosbuvir+veltapasvir) [29].
In conclusion, this experience adds evidence on the benefits of 
running systematic HCV “test and treat” programs in prisons in 
the era of new DAAs by creating well-coordinated networks. This 
pioneer program is feasible and economic, and political efforts 
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
✓✓ Prisons are major reservoirs of hepatitis c virus (HcV).
✓✓ there is a substantial risk of HcV transmission during 
incarceration.
✓✓ HcV treatment in prisons faces different challenges that so 
far have prevented its universal implementation.
WHAT IS NEW HERE
✓✓ A sustained and universal “test and treat” strategy in a 
prison led to the eradication of HcV.
✓✓ It also prevented new incident cases of HcV (i.e. intra-
prison transmission).
✓✓ the use of telemedicine favored the implementation of this 
strategy.
✓✓ Eradication of HcV in prisons is feasible and beneficial. 
spreading this strategy should entail a public health 
impact
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